HAEM5:Follicular lymphoma: Difference between revisions
| [unchecked revision] | [unchecked revision] |
Bailey.Glen (talk | contribs) No edit summary |
Bailey.Glen (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{Under Construction}} | {{Under Construction}} | ||
<blockquote class= | <blockquote class='blockedit'>{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Follicular Lymphoma]]. | ||
Other relevent pages include: [[HAEM4:Testicular Follicular Lymphoma]] | Other relevent pages include: [[HAEM4:Testicular Follicular Lymphoma]] | ||
| Line 90: | Line 90: | ||
<blockquote class= | <blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
<blockquote class= | <blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote>[1, 2, 3, 4]<blockquote class="blockedit"> | ||
<center><span style="color:Maroon">'''End of V4 Section'''</span> | |||
---- | |||
<blockquote class="blockedit"> | |||
<center><span style="color:Maroon">'''End of V4 Section'''</span> | |||
---- | |||
</blockquote> | |||
</blockquote> | </blockquote> | ||
==Sites of Involvement== | ==Sites of Involvement== | ||
| Line 103: | Line 109: | ||
<blockquote class= | <blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote>[1, 2, 3, 4]<blockquote class="blockedit"> | ||
<center><span style="color:Maroon">'''End of V4 Section'''</span> | |||
---- | |||
</blockquote> | |||
==Morphologic Features== | ==Morphologic Features== | ||
| Line 161: | Line 170: | ||
<blockquote class= | <blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
| Line 178: | Line 187: | ||
<blockquote class= | <blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote>[1, 2, 5, 7, 9, 11]<blockquote class="blockedit"> | ||
<center><span style="color:Maroon">'''End of V4 Section'''</span> | |||
---- | |||
<blockquote class="blockedit"> | |||
<center><span style="color:Maroon">'''End of V4 Section'''</span> | |||
---- | |||
</blockquote> | |||
</blockquote> | </blockquote> | ||
<blockquote class= | <blockquote class='blockedit'>{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in: | ||
* Chromosomal Rearrangements (Gene Fusions) | * Chromosomal Rearrangements (Gene Fusions) | ||
* Individual Region Genomic Gain/Loss/LOH | * Individual Region Genomic Gain/Loss/LOH | ||
* Characteristic Chromosomal Patterns | * Characteristic Chromosomal Patterns | ||
* Gene Mutations (SNV/INDEL)}} | * Gene Mutations (SNV/INDEL)}}</blockquote> | ||
Most common: Risk stratification using <u>F</u>ollicular <u>L</u>ymphoma <u>I</u>nternational <u>P</u>rognostic <u>I</u>ndex (FLIPI) is based on clinical indicators. | Most common: Risk stratification using <u>F</u>ollicular <u>L</u>ymphoma <u>I</u>nternational <u>P</u>rognostic <u>I</u>ndex (FLIPI) is based on clinical indicators. | ||
| Line 192: | Line 207: | ||
(m7-FLIPI adds performance status plus mutational status of ''EZH2'', ''ARID1A'', ''MEF2B'', ''EP300'', ''FOXO1'', ''CREBBP'' and ''CARD11'' - utility not confirmed [7]) | (m7-FLIPI adds performance status plus mutational status of ''EZH2'', ''ARID1A'', ''MEF2B'', ''EP300'', ''FOXO1'', ''CREBBP'' and ''CARD11'' - utility not confirmed [7]) | ||
<blockquote class="blockedit"> | |||
<center><span style="color:Maroon">'''End of V4 Section'''</span> | |||
---- | |||
</blockquote> | </blockquote> | ||
==Individual Region Genomic Gain / Loss / LOH== | ==Individual Region Genomic Gain / Loss / LOH== | ||
| Line 240: | Line 258: | ||
|} | |} | ||
<blockquote class= | <blockquote class='blockedit'>{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
deletions in 1p36, 6q, 10q, 13p, 17p; gains of 1q, 2p, 7, 8, 12q, 18q | deletions in 1p36, 6q, 10q, 13p, 17p; gains of 1q, 2p, 7, 8, 12q, 18q | ||
<blockquote class="blockedit"> | |||
<center><span style="color:Maroon">'''End of V4 Section'''</span> | |||
---- | |||
</blockquote> | </blockquote> | ||
==Characteristic Chromosomal Patterns== | ==Characteristic Chromosomal Patterns== | ||
| Line 267: | Line 288: | ||
|} | |} | ||
<blockquote class= | <blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
| Line 273: | Line 294: | ||
<blockquote class= | <blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote>[11]<blockquote class="blockedit"> | ||
<center><span style="color:Maroon">'''End of V4 Section'''</span> | |||
---- | |||
<blockquote class="blockedit"> | |||
<center><span style="color:Maroon">'''End of V4 Section'''</span> | |||
---- | |||
</blockquote> | |||
</blockquote> | </blockquote> | ||
==Gene Mutations (SNV / INDEL)== | ==Gene Mutations (SNV / INDEL)== | ||
| Line 309: | Line 336: | ||
<blockquote class= | <blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
Put your text here and/or fill in the tables | Put your text here and/or fill in the tables | ||
| Line 356: | Line 383: | ||
|} | |} | ||
<blockquote class="blockedit"> | |||
<center><span style="color:Maroon">'''End of V4 Section'''</span> | |||
---- | |||
</blockquote> | </blockquote> | ||
==Epigenomic Alterations== | ==Epigenomic Alterations== | ||
| Line 381: | Line 411: | ||
|} | |} | ||
<blockquote class= | <blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
''BCR-NFκB'', ''JAK/STAT''; ''mTORC'' signaling | ''BCR-NFκB'', ''JAK/STAT''; ''mTORC'' signaling | ||
<blockquote class="blockedit"> | |||
<center><span style="color:Maroon">'''End of V4 Section'''</span> | |||
---- | |||
</blockquote> | </blockquote> | ||
==Genetic Diagnostic Testing Methods== | ==Genetic Diagnostic Testing Methods== | ||